1 mL BAC
4 units
resulting U-100 draw
- Concentration
- 70 mg/mL
- BAC added
- 1 mL
BlendNot ApprovedMixedVery Low confidenceSourced
GLOW blend
A three-component GHK-Cu, BPC-157 and TB-500 research blend. No controlled human evidence establishes this combined formulation or schedule.
Evidence context, not a personal protocol
Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.
Community-reported schedule
Community-reported · not a validated scheduleCommunity dose schedule
A community GHK-Cu / BPC-157 / TB-4 healing blend at 50/10/10 mg (70 mg total), reconstituted in one vial and dosed subcutaneously by its GHK-Cu content. Total blend mass shown per injection; community reports only, not a validated schedule.
Reported maximum quantity
GHK-Cu-based daily dose (forum)
Choose the maximum quantity reported by this community line. Any earlier phase can be selected below for its arithmetic.Reported quantities by phase
Select a point for its calculation examples- Daily (GHK-Cu basis)~2.8 mg total50/10/10 mg blend (GHK-Cu / BPC-157 / TB-4); ~2.8 mg total delivers ~2 mg GHK-Cu plus ~0.4 mg each of BPC-157 and TB-4. Reports range ~1.5-5 mg GHK-Cu per day.
Vial-aware arithmetic
Reconstitution examples, up to 3 mL
Choose the vial quantity and BAC water first. The diagram and results below update for the selected ~2.8 mg total reported quantity. Higher-strength vials may naturally land outside the 20-30 unit band.
BAC water selected
3 mL
Basic example limit: 3 mL maximum. Check the actual vial and product-specific limits.
U-100 draw12 U
20-30 U reference band
2 mL BAC
8 units
resulting U-100 draw
- Concentration
- 35 mg/mL
- BAC added
- 2 mL
3 mL BAC
12 units
resulting U-100 draw
- Concentration
- 23.333 mg/mL
- BAC added
- 3 mL
Shown in the diagram. Closest of these examples to 25 units.
Formula: draw units = selected mg × BAC mL ÷ vial mg × 100. The 20-30 unit band is a measurement reference, not a recommendation. Results are mathematical examples, not preparation instructions.
Dosage and protocol evidence
Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.
Community GuideSubcutaneous in guideDaily for 4 weeks
Third-party educational schedule for a 70 mg GLOW blend
2.33 mg total daily for four weeks, approximately 1.67 mg GHK-Cu plus 0.33 mg BPC-157 and 0.33 mg TB-500 at the stated 50:10:10 ratio
The component split is blend-ratio arithmetic, not a controlled human dose. No study validates the combined formulation, route or four-week schedule.
View sourceCommunity GuideSubcutaneous in reportsUsually daily; sometimes split
online research community GLOW reports
Common vials are described as 50:10:10 mg or 50:20:10 mg GHK-Cu, BPC-157 and TB4; one explicit daily example delivers about 5 mg, 1 mg and 1 mg respectively
Other reports use substantially lower component quantities, and the channel explicitly calls GLOW an influencer-created recipe rather than an official protocol; raw/peptide-education/pe-ghk-cu.md:4470-4482 and 4999-5021.
View sourceCommunity GuideSubcutaneous in reportsUsually once daily; sometimes split
authenticated research-forum (Peppys) GLOW reports
A single-vial 50:10:10 mg GHK-Cu, BPC-157 and TB-4 blend (70 mg total) is dosed subcutaneously by its GHK-Cu content, most often about 2 mg GHK-Cu once daily (roughly 2.8 mg total blend, carrying about 0.4 mg each of BPC-157 and TB-4); reports range from about 1.5 to 5 mg GHK-Cu per day and are sometimes split morning and evening
Forum provenance from an authenticated archive with usernames and post numbers omitted. Component ratios and daily quantities conflict across reports, the blend is described as an influencer-named recipe rather than a validated protocol, and copper-load and angiogenesis cautions are noted. These quantities are community provenance, not controlled human dose finding.
View sourceEvidence summary
A three-component GHK-Cu, BPC-157 and TB-500 research blend. No controlled human evidence establishes this combined formulation or schedule.
Protocol basis
The name describes a commercial combination, not a clinical development programme. The page therefore reports only the separate evidence boundaries of its components.
Community provenance (Peppys)
An authenticated research-forum archive describes GLOW as a single-vial GHK-Cu, BPC-157 and TB-4 blend, most often at a 50:10:10 mg ratio, reconstituted together and dosed subcutaneously by its GHK-Cu content, commonly around 2 mg of GHK-Cu once daily with the BPC-157 and TB-4 riding along at a few hundred micrograms each. Reports range from roughly 1.5 to 5 mg of GHK-Cu per day, sometimes split between morning and evening, and the archive describes GLOW as an influencer-named recipe rather than an official protocol, noting copper-load and angiogenesis cautions. Reported quantities and ratios conflict, usernames and post numbers are omitted, and the figures are logged as community provenance without endorsement. The planner above reproduces the arithmetic of these reported quantities as a total blend mass; it does not validate them.
What remains uncertain
There are no matched human pharmacokinetic, compatibility, stability, safety or outcome data for the mixture.
Warnings and contraindications
No controlled human study of the three-component blend was identified.
Topical GHK-Cu evidence does not validate systemic use in a blend.
Component claims cannot demonstrate mixture stability, sterility or clinical benefit.
GLOW is an influencer/community name rather than a standardised formulation; component ratios vary across products and posts.
Shared across protocols
Supplies and general handling
Keep the universal checklist short. Product-specific labelling and source documentation always take priority over a general guide.
Research vial
Select the labelled vial quantity used in the calculation.
View Peppys vialBacteriostatic water
Use only a diluent appropriate to the research method and formulation.
View Peppys BAC waterU-100 measuring syringe
Use a new sterile device for every entry. Source locally.
Source locallyWipes and sharps container
Plan clean handling and immediate sharps disposal. Source locally.
Source locallyStorage follows the label
Do not apply a universal refrigerator rule. Follow the product, diluent and study documentation for temperature, light and expiry.
Use sterile equipment once
CDC injection-safety guidance calls for a new sterile needle and syringe for each injection and entry into a medication container.
Stability is formulation-specific
Do not infer a post-mixing lifetime from BAC water alone. Discard material when identity, integrity or sterility is in doubt.